Waldenstrom’s Macroglobulinemia: Advances in Treatments - Curetalks

Waldenstrom’s Macroglobulinemia: Advances in Treatments

Waldenstrom’s macroglobulinemia (WM) is a lymphoma, or cancer of the lymphatic system. The disease begins in a type of white blood cell called a B-lymphocyte, which normally matures into a plasma cell. In WM, there is a malignant change to the B-cell and it continues to proliferate into a clone of identical cells in the bone marrow, lymph nodes and other tissues and organs of the lymphatic system. 

The current standard treatments for WM consist of Rituxan (rituximab), Imbruvica (ibrutinib) combinations or monotherapy in the first- and second-line setting. Treatment is mainly focused on the control of symptoms and the prevention of organ damage. 

The CureTalks panel talks to Dr. Larry Anderson of UT Southwestern Medical Center and Dr. Rachid C. Baz of Moffitt Cancer Center on the current standards of care for WM, as well as  novel agents currently being evaluated. Joining the panel bringing in the patient perspective is advocate Meg Mangin. 

Panelists

Live Talk on Dec 01, 2021, 01:00 pm EST

     

    Add to Calendar

    CureTalks is an online Talk featuring a leading expert in conversation with a panel and the audience. The audience can ask questions from the panelists LIVE on the talk by dial-ing in. To hear the talk via phone or on-line, please add your email on the left; we will send you Live Talk access details. You can also write your questions in the Comments/Questions section below and your question maybe selected to be featured on the talk.


    Submit a question for the panelists or leave a comment below.

    Your email address will not be published. Required fields are marked *